ArticleDiscover oncology2025
Development of a novel 4-protein signature for prognostic prediction in hepatitis B virus-induced hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) remains a major global health challenge, with the pathogenesis of HBV-induced HCC incompletely understood. Due to HCC's significant heterogeneity, more accurate prognostic models and reliable biomarkers are urgently needed. This study aimed to develop such tools for HBV-related HCC.
methodsProtein expression profiles and clinicopathological data were obtained from the CPTAC (Clinical Proteomic Tumor Analysis Consortium) database. Differential protein expression analysis between HBV-induced HCC and normal tissues were performed, followed by univariate and multivariate Cox regression to construct a prognostic protein signature. The four-protein signature's prognostic power was assessed using time-dependent receiver operating characteristic (ROC) curves, Kaplan-Meier analysis, multivariate Cox regression, and a nomogram. Protein expression levels of the four proteins were validated in clinical specimens of HBV-related HCC. The signature was further validated in an independent cohort.
resultsA novel four-protein signature (SMC2, SMC4, UBE2C, UHRF1) was established for prognostic prediction in HBV-related HCC. ROC curves demonstrated good survival prediction performance in both the CPTAC HCC cohort and the validation cohort. Transcriptomic and immunohistochemical (IHC) analyses revealed significant overexpression of these four proteins at both mRNA and protein levels in HCC tissues. The signature stratified patients into high-risk and low-risk groups with significantly different survival outcomes. Multivariate Cox regression analysis confirmed that the 4-protein signature independently predicted overall survival (OS). Furthermore, the signature showed strong discriminatory power between HBV-related HCC and normal tissue. Time-dependent ROC analysis indicated that the protein signature exhibited superior specificity and sensitivity compared to alpha-fetoprotein (AFP) for diagnosing HBV-associated HCC.
conclusionsOur study establishes a novel 4-protein signature and nomogram for predicting OS in HBV-related HCC, potentially aiding individualized clinical treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.